Pay in 4 interest-free payments of $6.33 Learn more
Ships within 48 hours · Estimated delivery Oct 7 - Oct 12
March March 28 Product: Akebias Vafseo Indication: Anemia due to chronic kidney disease After a lengthy regulatory battle, the FDA approved Akebia Therapeutics oral treatment vadadustat
1-2 ,
To evaluate potential alternative acetyl-CoA producing pathways, we generated cancer cell lines in which ACLY and ACSS2 are genetically deleted individually or in combination
GHK-Cu has more skin and wound healing research
First Trusts suite of Target Outcome ETFs has amassed approximately $18 billion in total net assets as of 2/29/2024.* We are thrilled to expand First Trusts lineup of Target Income ETFs with the launch of FDND, which will enable investors to effectively harvest some of the volatility inherent in internet stocks by selling call options against a portion of its holdings, said Ryan Issakainen, CFA, Senior Vice President, ETF Strategist at First Trust
US$ 21.46
US$ 21.12
US$ 23.28
US$ 26.71
US$ 25.07
US$ 28.23
